Featured News

During the month of May, the Celiac Disease Foundation is taking the opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

Piecemeal solutions are no longer an option. It is time for a complete transformation of the health care system to promote unbiased structures and processes to advance equitable access to quality health care for all.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

Consider joining the LILY Study, a phase 1 clinical trial for people with celiac disease investigating DONQ52, a new potential celiac disease treatment.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

We are pleased to introduce a new 7-Day Mediterranean Diet Meal Plan, developed by Janelle Smith, Registered Dietitian at UCLA.

The risk of developing CAD in celiac patients was found to be higher for white males, and patients with celiac disease and CAD are more likely to have disorders such as high cholesterol, type 2 diabetes, and iron-deficiency anemia.  

Last week in Washington, D.C., the Celiac Disease Foundation and our allies secured two critical wins in our mission to drive policy change to improve the health of those living with celiac disease.

New research studying the association of celiac disease and inflammatory bowel disease (IBD) shows a strong relationship between the two conditions.